Pharma Focus Asia

EUROAPI Plans to Invest US$50 miilion (€50 million) to Open New Production Plant in Europe


EUROAPI invests US$50 million (€50 million) to establish a new production plant at its Budapest site, Europe.


The new state-of-the-art manufacturing plant will double Budapest site's prostaglandin production.
The upcoming production plant in Budapest is set to be a pioneering facility equipped with advanced features to promote sustainability and operational efficiency. 

The primary objective of this project is to address capacity limitations that the current manufacturing setup might be experiencing. 

This project is designed in two phases. The first phase, scheduled from 2023 to 2025 and accounting for approximately two-thirds of the total investment, will concentrate on overcoming existing bottlenecks and enhancing the production capacity. 

The second phase, spanning from 2026 to 2027, will focus on the construction and integration of new multi-purpose manufacturing equipment.

The facility is anticipated to play a pivotal role in fulfilling pharmaceutical manufacturing requirements while contributing positively to the environment and potential future developments in the field.

The new manufacturing facility will be operational by 2027.


Type    New Construction
Budget US$50 million(€50 million) 
Year   2027

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Asia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024